Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligonaphthofurans: fan-shaped and three-dimensional π-compounds.
Nakanishi K, Fukatsu D, Takaishi K, Tsuji T, Uenaka K, Kuramochi K, Kawabata T, Tsubaki K. Nakanishi K, et al. J Am Chem Soc. 2014 May 14;136(19):7101-9. doi: 10.1021/ja502209w. Epub 2014 May 1. J Am Chem Soc. 2014. PMID: 24738696
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Yoshimura A, Takeda T, Kataoka N, Tanimura K, Fukui M, Chihara Y, Takei S, Kawachi H, Nakanishi K, Yamanaka Y, Tamiya N, Honda R, Okura N, Yamada T, Uryu K, Murai J, Shiotsu S, Yoshioka H, Yamada T, Kurata T, Takayama K. Yoshimura A, et al. Among authors: nakanishi k. Front Oncol. 2024 Jan 26;14:1303543. doi: 10.3389/fonc.2024.1303543. eCollection 2024. Front Oncol. 2024. PMID: 38344209 Free PMC article.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K, Takeda T, Kataoka N, Yoshimura A, Nakanishi K, Yamanaka Y, Yoshioka H, Honda R, Uryu K, Fukui M, Chihara Y, Takei S, Kawachi H, Yamada T, Tamiya N, Okura N, Yamada T, Murai J, Shiotsu S, Kurata T, Takayama K. Tanimura K, et al. Among authors: nakanishi k. Cancers (Basel). 2023 Oct 14;15(20):4988. doi: 10.3390/cancers15204988. Cancers (Basel). 2023. PMID: 37894357 Free PMC article.
Ninjin'yoeito reduces fatigue-like conditions by alleviating inflammation of the brain and skeletal muscles in aging mice.
Otsuka S, Matsuzaki R, Kakimoto S, Tachibe Y, Kawatani T, Takada S, Tani A, Nakanishi K, Matsuoka T, Kato Y, Inadome M, Nojima N, Sakakima H, Mizuno K, Matsubara Y, Maruyama I. Otsuka S, et al. Among authors: nakanishi k. PLoS One. 2024 May 20;19(5):e0303833. doi: 10.1371/journal.pone.0303833. eCollection 2024. PLoS One. 2024. PMID: 38768175 Free article.
Protocol for the nationwide registry of patients with polycystic kidney disease: japanese national registry of PKD (JRP).
Nakatani S, Kawano H, Sato M, Hoshino J, Nishio S, Miura K, Sekine A, Suwabe T, Hidaka S, Kataoka H, Ishikawa E, Shimazu K, Uchiyama K, Fujimaru T, Moriyama T, Kurashige M, Shimabukuro W, Hattanda F, Kimura T, Ushio Y, Manabe S, Watanabe H, Mitobe M, Seta K, Shimada Y, Kai H, Katayama K, Ichikawa D, Hayashi H, Hanaoka K, Mochizuki T, Nakanishi K, Tsuchiya K, Horie S, Isaka Y, Muto S; JRP collaborators. Nakatani S, et al. Among authors: nakanishi k. Clin Exp Nephrol. 2024 May 11. doi: 10.1007/s10157-024-02509-3. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 38734869
2,943 results